Abstract: A controlled release tablet for once-daily oral administration of about 500-1200 mg of naproxen or naproxen sodium, said tablet comprising a homogeneous matrix comprising about 4-9 weight percent of hydroxypropyl methylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent naproxen or naproxen sodium, and 0.1 to about 2 weight percent of a pharmaceutically acceptable lubricating agent, and optionally including a pharmaceutically acceptable coating.

Abstract: A minipellet dosage form of prednisone or prednisolone, resistant to attack by saliva but readily dissolvable in gastric juice, which comprises a mixture of prednisone or prednisolone and polyvinylpyrrolidone coated onto a nonpareil seed, and further coated with a layer of dimethylaminoethyl and methyl methacrylate copolymer.

Abstract: A sustained release quindine dosage form is made from a plurality of pellets. Each pellet includes a quinidine-containing coating over a nonpareil seed, with a further coating of about 5 to about 15% by weight of a mixture of about 1.5 to about 9 parts by weight ethylcellulose to about 1 part by weight hydroxypropylcellulose.

Abstract: A controlled release tablet for once-daily oral administration of about 500-1200 mg of naproxen or naproxen sodium, said tablet being a homogeneous matrix comprising about 4-9 weight percent of hydroxypropylmethylcellulose having a number average molecular weight in the range of from about 80,000 to about 130,000, about 81-96 weight percent naproxen or naproxen sodium, 0.1 to about 2 weight percent of a pharmacetucailly acceptable lubricating agent, and 0 to about 8 weight percent of other pharmaceutically acceptable excipients.

Abstract: A method of providing a patient suffering from cardiac arrhythmia with a sustained dosage of propranolol over a prolonged period of time comprises orally administering to the patient a tablet consisting essentially of a therapeutically effective amount of propranolol to provide a sustained release thereof over a prolonged period of time which is contained in compressed granules having from about 0.1 to about 10 parts by weight hydroxypropyl methylcellulose and about one part by weight hydroxypropyl cellulose and a lubricant for the compressed granules.

Abstract: A tablet, which readily disintegrates in gastric fluid to give aspirin crystals coated with a polymeric film preventing the aspirin crystals from contacting the stomach wall but not preventing access of gastric fluid to the aspirin contained within the polymer film, which consists of a plurality of aspirin crystals 20-60 mesh in size coated with about 3-10% by weight of a polymeric mixture comprising from about 1.5 to about 15 parts by weight ethylcellulose and about one part by weight hydroxypropylcellulose; a compression aid; a disintegrant; and a tableting aid.

Abstract: A sustained release aspirin dosage form permits the continuous delivery of aspirin into the gastrointestinal tract for a period of at least eight hours. The sustained release aspirin dosage form comprises a plurality of polymerically coated aspirin crystals each of which comprises an aspirin seed. The majority of aspirin seeds have a mesh size of from about 30 to about 60 mesh. Each of the aspirin seeds is individually coated with a polymeric mixture, which comprises from about 1.5 to about 15 parts by weight ethylcellulose and about one part by weight hydroxypropylcellulose.